A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Summary

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Timeline

Start

2023-12-21

Primary completion

2027-11

Completion

2031-01

Publications

• Peters S, Hochmair M, Arbour KC, Rodriguez LP, Reck M, Leal T, R Lindsay C, Shun L, William WN, Spira AI, Sabari JK, Henning Gronberg B, Nishio M, Burns TF, Girard N, Capuzzo F, Merced A, Fasnacht N, Visseren-Grul C, Negrao MV. SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. Future Oncol. 2026 Apr;22(9):1073-1082. doi: 10.1080/14796694.2026.2651961. Epub 2026 Apr 6.

Drugs

Indications